Recursion Pharmaceuticals (RXRX) Director Borgeson Blake Sells 30,000 Shares

What Happened Blake Borgeson, a director of Recursion Pharmaceuticals, reported the sale of 30,000 shares on 2026-08-04 at $3.25 per share, for proceeds of $97,500. The filing lists the transaction as an open market or private sale (code S). This was a sale (not a purchase), which is often routine, especially when executed under a pre-established trading plan.

Key Details

• Transaction date and price: 2026-08-04, 30,000 shares at $3.25 each.
• Total value: $97,500.
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Footnote: Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 31, 2025.
• Filing timeliness: Form 4 was filed on 2026-08-06 (two days after the transaction), generally within the SEC’s 2-business-day reporting window.

Context A Rule 10b5-1 plan allows insiders to execute pre-planned trades at set times or under set conditions; sales under these plans are typically viewed as scheduled transactions rather than ad hoc signals about company prospects. For retail investors, purchases tend to be more informative about insider sentiment than routine sales executed under 10b5-1 plans.